Samsung Medical Center
π°π·South Korea
- Country
- π°π·South Korea
- Ownership
- Subsidiary
- Established
- 1994-01-01
- Employees
- 501
- Market Cap
- -
A Study to Validate the Safety and Feasibility of ArtiSential in Colorectal Cancer Surgery Using Prospectively Constructed Multi-center Registry
Recruiting
- Conditions
- Interventions
- First Posted Date
- 2022-10-04
- Last Posted Date
- 2022-10-06
- Lead Sponsor
- Samsung Medical Center
- Target Recruit Count
- 1000
- Registration Number
- NCT05566249
- Locations
- π°π·
Samsung Medical Center, Seoul, Korea, Republic of
Osimertinib to Suppress the Progression of Remaining GGN for EGFR Mutation-positive Stage IB-IIIA Lung Adenocarcinoma
- First Posted Date
- 2022-09-06
- Last Posted Date
- 2024-04-23
- Lead Sponsor
- Samsung Medical Center
- Target Recruit Count
- 59
- Registration Number
- NCT05528458
- Locations
- π°π·
Sehoon Lee, Seoul, Korea, Republic of
Revascularization Strategy of Multivessel Disease for Patients with Acute Myocardial Infarction Complicated by Cardiogenic Shock Undergoing Veno-arterial Extracorporeal Membrane Oxygenator
- First Posted Date
- 2022-09-02
- Last Posted Date
- 2024-11-06
- Lead Sponsor
- Samsung Medical Center
- Target Recruit Count
- 560
- Registration Number
- NCT05527717
- Locations
- π°π·
Samsung Medical Center, Seoul, Korea, Republic of
Relationship Between Effect Duration of Rocuronium and Body Composition Analysis Data.
- Conditions
- Interventions
- First Posted Date
- 2022-08-25
- Last Posted Date
- 2023-01-04
- Lead Sponsor
- Samsung Medical Center
- Target Recruit Count
- 88
- Registration Number
- NCT05515835
- Locations
- π°π·
Samsung Medical Center, Sungkyunkwan University, School of Medicine, Seoul, Korea, Republic of
Body Composition Analysis and Time to Emergence From Remimazolam
- Conditions
- Interventions
- First Posted Date
- 2022-08-23
- Last Posted Date
- 2023-01-04
- Lead Sponsor
- Samsung Medical Center
- Target Recruit Count
- 90
- Registration Number
- NCT05512559
- Locations
- π°π·
Samsung Medical Center, Sungkyunkwan University, School of Medicine, Seoul, Korea, Republic of
Phase II Study of Carfilzomib, Pomalidomide, and Dexamethasone for Myeloma Patients Who Had Relapsed or Progressed After Carfilzomib, Lenalidomide, and Dexamethasone
Phase 2
- Conditions
- Interventions
- First Posted Date
- 2022-08-22
- Last Posted Date
- 2022-08-22
- Lead Sponsor
- Samsung Medical Center
- Target Recruit Count
- 33
- Registration Number
- NCT05509374
- Locations
- π°π·
Samsung Medical Center, Seoul, Korea, Republic of
Carfilzomib, Lenalidomide, and Dexamethasone Re-induction Followed by the 2nd ASCT in Multiple Myeloma Patients Relapsed After the 1st ASCT
- First Posted Date
- 2022-08-11
- Last Posted Date
- 2022-08-12
- Lead Sponsor
- Samsung Medical Center
- Target Recruit Count
- 58
- Registration Number
- NCT05497102
- Locations
- π°π·
Samsung Medical Center, Seoul, Korea, Republic of
The Prognostic Role and Diagnostic Efficacy of Exercise Right Heart Catheterization With a Simultaneous Echocardiography in Patients With Dyspnea on Exertion
Recruiting
- Conditions
- Interventions
- First Posted Date
- 2022-08-08
- Last Posted Date
- 2022-08-08
- Lead Sponsor
- Samsung Medical Center
- Target Recruit Count
- 400
- Registration Number
- NCT05490901
- Locations
- π°π·
Samsung Medical Center, Seoul, Korea, Republic of
Atorvastatin Use and Portal Hypertension in Patients With Hepatitis B Virus-related Liver Cirrhosis: A Randomized Controlled Trial
Phase 2
Not yet recruiting
- Conditions
- Interventions
- First Posted Date
- 2022-08-02
- Last Posted Date
- 2022-08-02
- Lead Sponsor
- Samsung Medical Center
- Target Recruit Count
- 36
- Registration Number
- NCT05483894
Hypofractionated IMRT With Concurrent Chemotherapy in Muscle-invasive Bladder Cancer (HIRACUM)
- First Posted Date
- 2022-07-12
- Last Posted Date
- 2024-12-02
- Lead Sponsor
- Samsung Medical Center
- Target Recruit Count
- 53
- Registration Number
- NCT05453682
- Locations
- π°π·
Samsung Medical Center, Seoul, Korea, Republic of
Β© Copyright 2024. All Rights Reserved by MedPath